

Section 5 – Other Events

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 11, 2017, Tae Heum Jeong, Senior Vice President of Finance, Chief Financial Officer and Secretary of Rexahn Pharmaceuticals, Inc. (the “Company”), informed the Company of his resignation from all positions at the Company effective March 15, 2018, in order to pursue another opportunity.

Dr. Jeong and the Company have entered into an agreement (the “Agreement”) to formalize the terms of Dr. Jeong’s resignation and to provide for an arrangement pursuant to which Dr. Jeong has agreed to provide transition and advisory services through March 15, 2019, including assistance with financial reporting, financial matters, strategic planning, investor relations and business development activities. Dr. Jeong will receive total cash compensation of \$100,000, payable in four equal installments, as consideration for these services, and all outstanding equity awards granted to Dr. Jeong by the Company will continue to vest in accordance with their terms until March 15, 2019 or such earlier date on which the Agreement is terminated.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement, a copy of which the company intends to file as an exhibit to its Annual Report on Form 10-K for the year ending December 31, 2017.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REXAHN PHARMACEUTICALS, INC.

Date: December 12, 2017

/s/ Peter D. Suzdak

Peter D. Suzdak

Chief Executive Officer
